Novartis to acquire Avidity Bio for $12B

Avidity Biosciences brings to Novartis three RNA therapies in pivotal testing for rare neuromuscular diseases along with the technology that produced them. This platform develops drugs in a new class of targeted medicines offering potential to expand the delivery of RNA treatments beyond the liver.

Editor's Pick

Top Story Novartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition Avidity Biosciences brings to Novartis three RNA therapies in pivotal testing for rare neuromuscular diseases along with the technology that produced them. This platform develops drugs in a new class of targeted medicines offering potential to expand the delivery of RNA treatments beyond the liver. Sponsored Simplifying Complexity: NICU Revenue Code Issues Presented by ProgenyHealth Today, infants are surviving at increasingly younger gestational ages—sometimes as early as 22 weeks. These remarkable advancements, however, come with significant financial implications. NICU claims can easily reach hundreds of thousands of dollars, especially when submitted under a single revenue code level that doesn't reflect the actual intensity or duration of care. To make sense of the clinical and financial implications of NICU care click here.

Featured News

Heard at HLTH: Streamlining Administrative Tasks and Improving Workflows with AI (Video) [Sponsored] In interviews with MedCity News Reporter Marissa Plescia and Editor-in-Chief Arundhati Parmar, healthcare executives offered updates on their companies and their outlook. How Hospitals Are Keeping Up with the Rapid Rise of AI At MedCity News' Tête-à-tête Health event, executives from Sutter Health and Tampa General Hospital discussed how they are deploying AI, as well as how they are keeping governance and the human touch at the forefront. Why the Women's Health Space Needs to Expand Beyond Reproductive Health Health tech company Visana is urging the women's health industry to expand its focus beyond reproductive care to address broader issues like cardiometabolic health, obesity and hormonal conditions that affect the majority of women outside the family-building years. Bayer Menopause Drug Lands FDA Approval, Bringing Competition to an Astellas Product Bayer's Lynkuet, approved for treating moderate-to-severe vasomotor symptoms of menopause, targets two receptors key to temperature regulation. The once-daily pill came from Bayer's 2020 acquisition of KaNDy Therapeutics. Innovations Offer Hope in the Fight Against Antibiotic Resistance Antibiotic resistance is a growing global threat with serious health and economic consequences. Yet there is progress – from rapid PCR diagnostics and AI-driven research to new drug development and innovative funding models. Phony Bank Account Change Requests: A Growing Threat for Healthcare Finance Leaders Phony bank account change requests aren't just another check box on a fraud prevention list – they're one of the most immediate and dangerous threats facing healthcare AP teams today.

Video   Virtual OUD Treatment Is Proving Valuable A report from the Peterson Health Technology Institute found that virtual opioid use disorder companies are just as effective as standard in-person treatment — and they can improve retention. For a long time, the OUD treatment community believed that care needed to be delivered in person, noted Caroline Pearson, an executive director at Peterson Health Technology Institute. However, particularly since the pandemic, virtual care has proven to be effective and convenient, especially in place where there aren't many providers.

Resources

Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care Choosing the wrong EMR can slow your practice down. This guide helps healthcare teams compare options, avoid costly pitfalls, and choose a platform that improves care, compliance, and patient experience. View Now

MedCity News • PO Box 901 • New York, NY unsubscribe